Genescience Pharmaceuticals Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα (H1047R mutant), reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum.
Scientists at Atmosr SAS and Medetia SAS have synthesized adenine derivatives acting as heat shock protein 90 (HSP90) inhibitors reported to be useful for the treatment of cancer, neurodegenerative diseases, infections, myelofibrosis, acute pancreatitis, psoriasis and ROHHAD (rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation).
Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders.
Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential thrombocythemia, among others.
Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.
Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Researchers at McGill University and Neurasic Therapeutics Inc. have described substituted thiophene fused cyclohexanone derivatives acting as acid-sensing ion channel 1 (ASIC1) blockers reported to be useful for the treatment of pain, particularly neuropathic and inflammatory pain.
RSS